FDA Accepts Bristol Myers Squibb's Iberdomide for Relapsed/Refractory Multiple Myeloma

FDA has accepted the new drug application for iberdomide, the lead candidate in a new class of medicines, cereblon E3 ligase modulator (CELMoD) agents, which are designed to utilize targeted protein degradation (TPD) to address therapeutically relevant proteins.¹ Iberdomide has the potential to become the first approved member of the CELMoD class. The application, which has been granted priority review and breakthrough therapy designation, focuses on the treatment of patients with relapsed or refractory multiple myeloma (RRMM) using a combination of iberdomide, daratumumab, and dexamethasone, a regimen referred to as IberDd.

How Does This Application Influence the Landscape of Targeted Protein Degradation and Oral Oncology Treatments?

The development of iberdomide by Bristol Myers Squibb represents a strategic expansion of TPD beyond traditional immunomodulatory drugs.¹ Through a three-pronged research approach that leverages CELMoD agents, ligand-directed degraders, and degrader antibody conjugates, researchers aim to match specific therapeutic modalities to molecular mechanisms more effectively. During the first stage of the Phase III EXCALIBER-RRMM trial, investigators identified 1.0 mg as the optimal dose for iberdomide based on an analysis of its pharmacokinetics, safety, and efficacy. Regarding the clinical implications of this modality, Cristian Massacesi, executive vice president and chief medical officer at Bristol Myers Squibb, stated in a press release,¹ “The FDA’s acceptance of this application is a testament to the potential of iberdomide, in combination with anti-CD38 monoclonal antibodies, as a novel, potent, oral treatment option, with a manageable safety profile, for patients with multiple myeloma.”

Why Is the Focus on Minimal Residual Disease Significant for Regulatory Pathways?

A defining feature of the iberdomide submission is its use of minimal residual disease (MRD) negativity as a primary endpoint in the ongoing Phase III EXCALIBER-RRMM study.¹ The use of MRD provides a highly sensitive tool for evaluating treatment response by detecting small numbers of cancer cells that remain after therapy. Current detection methods, such as next-generation sequencing and next-generation flow cytometry, can identify a single malignant cell among 1 million normal cells. Regulatory authorities are increasingly recognizing MRD as a meaningful surrogate endpoint for progression-free survival, which can significantly accelerate the timelines for therapeutic development.

As Massacesi noted,¹ “Furthermore, our filing for iberdomide based on the MRD endpoint, underscores our commitment to pioneering new ways of advancing life-saving therapies for patients living with cancer.” This strategy is in line with FDA’s Project Orbis initiative, which allows for a concurrent review of the iberdomide application by health authorities in several other countries. While the initial filing is based on MRD data, the EXCALIBER-RRMM study—which randomized approximately 664 patients to receive either the IberDd regimen or a standard combination of daratumumab, bortezomib, and dexamethasone—continues to evaluate secondary endpoints such as overall survival and PFS to confirm long-term clinical outcomes.

How Is Bristol Myers Squibb Working Toward Other Cancer Innovations?

Beyond novel modalities like cereblon E3 ligase modulators, the industry is increasingly integrating digital health solutions to optimize patient identification.² A collaboration between Bristol Myers Squibb and Microsoft utilizes AI to enhance the early detection of lung cancer. By deploying algorithms through a precision imaging network, this initiative assists radiologists in identifying pulmonary nodules on routine imaging, which is critical since many findings are often lost to follow-up. This approach facilitates the transition of patients to precision therapies. Dr. Alexandra Goncalves noted in a press release,² “By combining Microsoft’s highly scalable radiology solutions with BMS’ deep expertise in oncology and drug delivery, we’ve envisioned a unique AI-enabled workflow that helps clinicians quickly and accurately identify patients with Non-Small Cell Lung Cancer (NSCLC) and guide them to optimal care pathways and precision therapies.” Integrating tools like AI supports a strategy for treating non-small cell lung cancer by improving efficiency and addressing health disparities. This ensures that life-saving treatments from BMS reach underserved populations effectively.

References

1. Bristol Myers Squibb. U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma. Bristol Myers Squibb Newsroom. 2026. Available at: https://news.bms.com/news/corporate-financial/2026/U-S--Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-New-Drug-Application-for-Iberdomide-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx. Accessed February 17, 2026.
2. Bristol Myers Squibb. Bristol Myers Squibb announces collaboration with Microsoft to advance AI-driven early detection of lung cancer. Bristol Myers Squibb Newsroom. 2026. Available at: https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Collaboration-with-Microsoft-to-Advance-AI-Driven-Early-Detection-of-Lung-Cancer/default.aspx. Accessed February 17, 2026.